Precigen Inc Total Liabilities
Precigen Inc total liabilities. Based on the latest financial reports, Precigen Inc (PGEN) has total liabilities worth $126.72 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check PGEN financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Precigen Inc (2011–2025)
Total liabilities of Precigen Inc from 2011 to 2025. This chart illustrates how Precigen Inc's total liabilities have evolved over time, based on quarterly financial data. Explore Precigen Inc (PGEN) investment intensity to see how much of total assets are deployed in long-term investments.
Precigen Inc Competitors by Total Liabilities
The table below lists competitors of Precigen Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
People.Cn Co Ltd
SHG:603000
|
China | CN¥1.52 Billion |
|
Enerflex Ltd.
NYSE:EFXT
|
USA | $1.58 Billion |
|
Inari Amertron Bhd
KLSE:0166
|
Malaysia | RM308.02 Million |
|
P/F Bakkafrost
F:6BF
|
Germany | €7.85 Billion |
|
BitVentures Limited
NASDAQ:BVC
|
USA | $23.99K |
|
GN Store Nord
CO:GN
|
Denmark | Dkr18.33 Billion |
|
China Baoan Group Co Ltd
SHE:000009
|
China | CN¥33.71 Billion |
|
KANSAI PAINT SPON.ADR/1/2
F:KAP0
|
Germany | €403.87 Billion |
Liability Composition Analysis (2011–2025)
This chart breaks down Precigen Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Precigen Inc.
Liquidity & Leverage Metrics
Precigen Inc Total Liabilities Ratios Explained
Precigen Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.58 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.91 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.74 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Precigen Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Precigen Inc (2011–2025)
The table below shows the annual total liabilities of Precigen Inc from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $135.71 Million | +27.13% |
| 2024-12-31 | $106.75 Million | +228.02% |
| 2023-12-31 | $32.55 Million | -63.73% |
| 2022-12-31 | $89.72 Million | -64.47% |
| 2021-12-31 | $252.51 Million | +2.06% |
| 2020-12-31 | $247.41 Million | -35.58% |
| 2019-12-31 | $384.05 Million | +13.81% |
| 2018-12-31 | $337.45 Million | +12.37% |
| 2017-12-31 | $300.31 Million | -20.93% |
| 2016-12-31 | $379.82 Million | +37.04% |
| 2015-12-31 | $277.16 Million | +65.98% |
| 2014-12-31 | $166.98 Million | +89.48% |
| 2013-12-31 | $88.13 Million | -81.38% |
| 2012-12-31 | $473.20 Million | +40.80% |
| 2011-12-31 | $336.09 Million | -- |
About Precigen Inc
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors… Read more